Evidence map›Paper›PMID 32849934›Full record

ReviewJournal of clinical medicine research2020

Exploring Repurposing Potential of Existing Drugs in the Management of COVID-19 Epidemic: A Critical Review.

Debjit Chakraborty, Falguni Debnath, Subrata Biswas, Mihir Bhatta, Suman Ganguly, Alok Kumar Deb, Malay Kumar Saha, Shanta Dutta

Open access · diamondAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of clinical medicine research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
0.3field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. A novel approach to managing COVID-19 patients; results of lopinavir plus doxycycline cohort.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2021
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Debjit ChakrabortyICMR-National Institute of Cholera and Enteric Disease, Kolkata, India.
Falguni DebnathICMR-National Institute of Cholera and Enteric Disease, Kolkata, India.
Subrata BiswasICMR-National Institute of Cholera and Enteric Disease, Kolkata, India.
Mihir BhattaICMR-National Institute of Cholera and Enteric Disease, Kolkata, India.
Suman GangulyWest Bengal State AIDS Prevention and Control Society, West Bengal, India.
Alok Kumar DebICMR-National Institute of Cholera and Enteric Disease, Kolkata, India.
Malay Kumar SahaICMR-National Institute of Cholera and Enteric Disease, Kolkata, India.
Shanta DuttaICMR-National Institute of Cholera and Enteric Disease, Kolkata, India.
National Institute of Cholera and Enteric Diseases · INWest Bengal State Council of Technical Education · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite high morbidity and mortality of ongoing coronavirus disease 2019 (COVID-19) pandemic, no specific therapy has been established till date. Though

Indexed as

COVID-19HCQRemdesivirRepurposing

Identifiers

PMID32849934
PMCPMC7430870
OpenAlexW3043900170

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.